After recently raising $175 million for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib, Avalyn Pharma has announced four new executive hires. The new appointments include former Boehringer Ingelheim interstitial lung disease (ILD) expert Craig Conoscenti as Senior VP, clinical development; Jim Bishop as Senior VP, Business Operations; … [Read more...] about Avalyn Pharma announces appointment of four executives
News
Biopas submits marketing applications for Inbrija levodopa DPI in six Central and South American countries
According to Acorda Therapeutics, Biopas Laboratories has submitted marketing applications for Inbrija levodopa inhalation powder for the treatment of OFF episodes in Parkinson's disease in Argentina, Colombia, Costa Rica, Ecuador, Panama, and Peru. In May 2022, Biopas acquired the rights to Inbrija in those 6 countries, plus Brazil, Chile, and Mexico. Acorda says … [Read more...] about Biopas submits marketing applications for Inbrija levodopa DPI in six Central and South American countries
New paper from IPAC-RS discusses methods for APSD testing of aqueous nasal sprays
The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC‑RS) is highlighting the recent publication of a new paper titled "Laboratory Performance Testing of Aqueous Nasal Inhalation Products for Droplet/Particle Size Distribution: an Assessment from the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC‑RS)" … [Read more...] about New paper from IPAC-RS discusses methods for APSD testing of aqueous nasal sprays
Inhalon Biopharma licenses human metapneumovirus antibodies for inhaled delivery
Inhalon Biopharma announced that it has licensed human metapneumovirus (hMPV) antibodies from the University of Georgia and intends to develop inhaled hMPV antibodies for the treatment of hMPV respiratory infections. According to the company's website, its pipeline includes a candidate designated IN-003 against hMPV. Inhalon's pipeline of inhaled therapies based … [Read more...] about Inhalon Biopharma licenses human metapneumovirus antibodies for inhaled delivery
United Therapeutics initiates Phase 3 TETON PPF study of Tyvaso treprostinil inhalation solution in patients with progressive pulmonary fibrosis
United Therapeutics has announced the initiation of the 52-week TETON PPF trial, which will evaluate the efficacy of Tyvaso treprostinil inhalation solution in almost 700 patients with progressive pulmonary fibrosis (PPF). The company said that the effort to expand the use of Tyvaso to patients with PPF with or without pulmonary hypertension (PH) is based on data from … [Read more...] about United Therapeutics initiates Phase 3 TETON PPF study of Tyvaso treprostinil inhalation solution in patients with progressive pulmonary fibrosis
SyqeAir cannabis inhaler gets TGA approval
According to Syqe Medical, Australia's Therapeutic Goods Administration (TGA) has approved the company's SyqeAir cannabis inhaler, which includes 60 metered doses of milled cannabis flowers. The cartridge-based inhaler will now appear in the Australian Register of Therapeutic Goods (ARTG). Novachem sponsored the application and will distribute SyqeAir in Australia. … [Read more...] about SyqeAir cannabis inhaler gets TGA approval
Transpire Bio opens new headquarters and research facility
Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced deals with Recipharm for development of 4 inhaled formulations (TRB-1, TRB-2, TRB-3, and TRB-4) and with INTO for 3 additional … [Read more...] about Transpire Bio opens new headquarters and research facility
MannKind gets US patent covering clofazimine inhalation suspension
According to MannKind Corporation, the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,793,808 ("Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them"), which covers the company's MNKD-101 clofazimine inhalation suspension, until 2039. MannKind is developing MNKD-101 … [Read more...] about MannKind gets US patent covering clofazimine inhalation suspension
University of Sydney researchers get $687,000 in FDA funding for development of in vitro testing methods for DPIs
Researchers at the University of Sydney have been awarded $687,000 by the FDA to support a project titled, "Development of a laser-based testing platform for generic dry powder inhaler DPI evaluation and in-silico model validation," the university said. The project is led by Hak-Kim Chan of the Sydney Pharmacy School and Agisilaos Kourmatzis of the School of … [Read more...] about University of Sydney researchers get $687,000 in FDA funding for development of in vitro testing methods for DPIs
FDA accepts AstraZeneca’s sBLA for self-administration of FluMist Quadrivalent intranasal flu vaccine
According to AstraZeneca, the FDA has accepted for review the company's supplemental biologics license application (sBLA) for self-administration of FluMist Quadrivalent nasal spray vaccine against influenza. AstraZeneca says that it expects a PDUFA date in the first quarter of 2024, which would allow for self administration of FluMist for the 2024-25 flu season if … [Read more...] about FDA accepts AstraZeneca’s sBLA for self-administration of FluMist Quadrivalent intranasal flu vaccine